• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.

作者信息

Maron Barry J

机构信息

Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 620, Minneapolis, MN 55407, USA.

出版信息

Circulation. 2010 Jan 26;121(3):445-56. doi: 10.1161/CIRCULATIONAHA.109.878579.

DOI:10.1161/CIRCULATIONAHA.109.878579
PMID:20100987
Abstract
摘要

相似文献

1
Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.肥厚型心肌病猝死风险分层与预防的当代见解和策略
Circulation. 2010 Jan 26;121(3):445-56. doi: 10.1161/CIRCULATIONAHA.109.878579.
2
Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator.肥厚型心肌病与猝死：植入式心脏复律除颤器在风险分层与预防方面的新视角
Eur Heart J. 2000 Dec;21(24):1979-83. doi: 10.1053/euhj.2000.2238.
3
Sudden cardiac death in hypertrophic cardiomyopathy.
J S C Med Assoc. 2001 Oct;97(10):424-7.
4
Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy.肥厚型心肌病心脏性猝死的风险评估与预防
Arch Mal Coeur Vaiss. 1996 Feb;89 Spec No 1:37-49.
5
Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.非侵入性风险分层可预防肥厚型心肌病患者因阵发性心房颤动导致的猝死。
J Cardiovasc Med (Hagerstown). 2006 Sep;7(9):711-3. doi: 10.2459/01.JCM.0000243007.97793.0f.
6
Gaps in Evidence for Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy.肥厚型心肌病心脏性猝死风险分层的证据缺口
Circulation. 2021 Jan 12;143(2):101-103. doi: 10.1161/CIRCULATIONAHA.120.051968. Epub 2021 Jan 11.
7
Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy.肥厚型心肌病、致心律失常性右室心肌病和扩张型心肌病猝死的一级预防。
J Cardiovasc Electrophysiol. 2005 Sep;16 Suppl 1:S28-34. doi: 10.1111/j.1540-8167.2005.50116.x.
8
Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification.肥厚型心肌病及年轻竞技运动员心源性猝死的其他原因，以及对参赛前筛查和 disqualification 标准的考量。 注：这里“disqualification”直译为“取消资格”，结合语境可能有更专业准确的医学术语表述，比如“禁赛标准”等，可根据具体医学领域进一步优化。
Cardiol Clin. 2007 Aug;25(3):399-414, vi. doi: 10.1016/j.ccl.2007.07.006.
9
[Prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy].[植入式除颤器预防肥厚型心肌病猝死]
Rev Esp Cardiol. 2006 Jun;59(6):527-30.
10
Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.植入式心脏除颤器与肥厚型心肌病猝死的预防
J Cardiovasc Electrophysiol. 2008 Oct;19(10):1118-26. doi: 10.1111/j.1540-8167.2008.01147.x. Epub 2008 Mar 31.

引用本文的文献

1
Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysis.钆延迟强化在心脏磁共振成像中对肥厚型心肌病非持续性室性心动过速和心源性猝死的预后价值：一项荟萃分析。
Eur Radiol. 2025 Aug 20. doi: 10.1007/s00330-025-11961-y.
2
Comparison of two genetic strategies for diagnostic work-up of hypertrophic cardiomyopathy: impact on the diagnosis of Fabry disease or transthyretin amyloidosis.肥厚型心肌病诊断检查的两种基因策略比较：对法布里病或转甲状腺素蛋白淀粉样变性诊断的影响
Orphanet J Rare Dis. 2025 Jun 10;20(1):294. doi: 10.1186/s13023-025-03815-z.
3
Reduction in myofilament Ca sensitivity partially ameliorates the cardiac phenotype in hypertrophic cardiomyopathy linked to a TnT-R92Q mutation.
肌丝对钙离子敏感性的降低部分改善了与肌钙蛋白T-R92Q突变相关的肥厚型心肌病的心脏表型。
Front Physiol. 2025 May 23;16:1600117. doi: 10.3389/fphys.2025.1600117. eCollection 2025.
4
The relationship between serum Lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者血清亮蛋白聚糖水平与心肌纤维化的关系。
Biomark Med. 2025 Mar;19(6):187-195. doi: 10.1080/17520363.2025.2473304. Epub 2025 Mar 3.
5
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.《2024年墨西哥肥厚型心肌病诊断与治疗指南》
Arch Cardiol Mex. 2024;94(Supl 4):1-75. doi: 10.24875/ACM.M25000098.
6
Contribution of hypoxia-inducible factor 1alpha to pathogenesis of sarcomeric hypertrophic cardiomyopathy.缺氧诱导因子1α在肌节性肥厚型心肌病发病机制中的作用
Sci Rep. 2025 Jan 16;15(1):2132. doi: 10.1038/s41598-025-85187-9.
7
Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.细胞角蛋白 18 作为肥厚型心肌病患者的新型生物标志物。
Cells. 2024 Aug 9;13(16):1328. doi: 10.3390/cells13161328.
8
Exploring Hypertrophic Cardiomyopathy Biomarkers through Integrated Bioinformatics Analysis: Uncovering Novel Diagnostic Candidates.通过综合生物信息学分析探索肥厚型心肌病生物标志物：发现新型诊断候选物
Cardiol Res Pract. 2024 Jul 4;2024:4639334. doi: 10.1155/2024/4639334. eCollection 2024.
9
Cellular models and therapeutic perspectives in hypertrophic cardiomyopathy.肥厚型心肌病的细胞模型与治疗前景
Med Genet. 2021 Dec 3;33(3):235-243. doi: 10.1515/medgen-2021-2094. eCollection 2021 Sep.
10
Integrative analysis of transcriptome, DNA methylome, and chromatin accessibility reveals candidate therapeutic targets in hypertrophic cardiomyopathy.转录组、DNA 甲基化组和染色质可及性的综合分析揭示了肥厚型心肌病的候选治疗靶点。
Protein Cell. 2024 Nov 1;15(11):796-817. doi: 10.1093/procel/pwae032.